Trials / Completed
CompletedNCT02644798
Nucleotide Polymorphism in ARDS Outcome
Nucleotide Polymorphism in ARDS Outcome: a Whole Exome Sequencing Association Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 105 (actual)
- Sponsor
- Southeast University, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Acute respiratory distress syndrome (ARDS) is characterized by increased pulmonary vascular permeability and reduced aerated lung tissue. With an extremely high hospital mortality among 35 - 46%, current therapeutic strategies to increase ARDS survival are still limited. Advances in etiology and pathology of ARDS are urging. Numerous genetic variants were identified associated with ARDS outcome. By whole-exome sequencing association study, our goal was to explore the associations between genetic variants and ARDS outcome.
Detailed description
Acute respiratory distress syndrome (ARDS) is characterized by increased pulmonary vascular permeability and reduced aerated lung tissue. With an extremely high hospital mortality among 35 - 46%, current therapeutic strategies to increase ARDS survival are still limited. Advances in etiology and pathology of ARDS are urging. Numerous genetic variants were identified associated with ARDS outcome. Then a few genetic risk factors have been discovered by large-scale genotyping approaches, from in vivo or in vitro models of lung injury, which highlight the importance of identifying genetic biomarkers of ARDS outcome to further improve stratification. The mutational landscape and variability at single nucleotide polymorphisms (SNP) with ARDS outcome in Chinese is unknown, not to mention their associations. By whole-exome sequencing association study, our goal was to explore the associations between genetic variants and ARDS outcome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Baseline-recorded data recorded | Baseline-recorded data recorded. Peripheral blood samples were drawn. |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-12-01
- Completion
- 2017-06-30
- First posted
- 2016-01-01
- Last updated
- 2022-03-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02644798. Inclusion in this directory is not an endorsement.